Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 8.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
It turns out, fresh estimates have trended upward during the past month.
The consensus estimate has shifted 6.92% due to these changes.
Currently, Qiagen has a nice Growth Score of B, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Qiagen has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Qiagen belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY), has gained 12.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.
Incyte reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +19.5%. EPS of $1.16 for the same period compares with $0.64 a year ago.
For the current quarter, Incyte is expected to post earnings of $1.38 per share, indicating a change of +175.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.6% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Incyte. Also, the stock has a VGM Score of A.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
Incyte Corporation (INCY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Why Plug Power Stock Keeps Going Up
Plug Power is teaming up with Australian partner Allied Green Ammonia to build a hydrogen plant in Uzbekistan. Plug Power's CFO just bought 650,000 more shares of the company. The CFO now owns 2.6 million Plug shares, which are worth a lot more than they were worth on Friday. 10 stocks we like better than Plug Power › Are investors in Plug Power (NASDAQ: PLUG) stock irrationally exuberant? Yesterday, shares of the hydrogen fuel cell manufacturer surged to close 26% higher after announcing an expanded strategic collaboration with Australian partner Allied Green Ammonia, whereby the two companies will build a $5.5 billion green chemical production facility in Uzbekistan, and there produce electrolyzer to create hydrogen fuel. Today, Plug Power stock is up another 16% through 10:15 a.m. ET. Are any other catalysts fueling Plug Power's rise? Turns out, there are. Yesterday, I was unimpressed by Plug's announcement of the Uzbekistan project, which Plug boasted created a "5 GW partnership now spanning two continents" between itself and Allied Green Ammonia. After all, the companies' Australian project hasn't yet received a "final investment decision," while the Uzbekistan deal is in even earlier stages. It all seems very hypothetical to me. Plug Power's own CFO, Paul Middleton, though, seems to see things differently. In a sterling example of putting money where one's mouth is, Middleton yesterday purchased an additional 650,000 Plug Power shares on the open market, the same day the Uzbekistan deal was announced. Priced at $1.03 per share, that's a $672,000 bet that Plug Power stock is the real deal. And to drive the point home, Middleton added, "This additional investment reflects my strong conviction in Plug's strategy and long-term value creation." Still, there are other ways to view Middleton's investment. Middleton already owned nearly 2 million Plug shares before yesterday's purchase, which are now worth $0.43 per share more than they were worth last week. His net worth just jumped by more than $800,000. If nothing else, yesterday's news just created a lot of value for Plug's CFO. Before you buy stock in Plug Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Plug Power Stock Keeps Going Up was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Is Boeing's Growth Still Shackled by Continued Problems in Its 737 Program?
The Boeing Company BA has successfully weathered much of the turbulence in its commercial aerospace segment since the pandemic, steadily charting a path toward recovery in recent quarters. However, its 737 MAX program remains under intense scrutiny as we progress in 2025, with the aerospace giant still grappling with lingering challenges that have constrained its growth trajectory. Following the January 2024 door-plug detachment incident involving Alaska Airlines Flight 1282, the Federal Aviation Administration ('FAA') imposed a cap of 38 737 jets per month. Boeing only reached this rate for the first time in May 2025. While CEO Kelly Ortberg has expressed confidence (as per major media reports) in raising production to 42 jets per month and eventually 47 by year-end, these targets appear too optimistic amid ongoing industry headwinds like labor shortages and parts supply constraints. Notably, Spirit AeroSystems SPR, Boeing's primary supplier of 737 fuselages, continues to face financial strain, operational inefficiencies and quality control issues, all of which had previously affected Boeing's output and could once again delay production. And even if we assume that these industry challenges do not worsen any further, the FAA's increased oversight and stringent inspection regime add another layer of complexity. Whether Boeing will secure regulatory clearance in time to ramp up production thus remains uncertain. While it is encouraging that Boeing delivered more 737s in first-quarter 2025 — boosting its commercial unit's revenue by 56.7% — questions remain about the sustainability of this growth under the shadow of regulatory, labor and supplier-related risks. The supply-chain constraints hampering the aerospace industry have affected almost all the industry players, with Boeing's arch-rival, Airbus Group EADSY, being no exception. This European plane maker had to slash its production target for 2024, citing supply-chain issues as the prime reason behind it. However, recently Airbus appears to be managing supply-chain disruptions more effectively than Boeing, as reflected in its higher aircraft deliveries in first-quarter 2025. Notably, Airbus delivered 136 commercial aircraft in the first quarter compared with Boeing's 130. Shares of Boeing have risen 20.6% year to date compared with the Zacks aerospace-defense industry's growth of 25.5%. Image Source: Zacks Investment Research From a valuation standpoint, BA is currently trading at a forward 12-month sales multiple of 1.80X, a roughly 17.4% discount when stacked up with the industry average of 2.18X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BA's 2025 and 2026 sales implies a year-over-year uptick of 25.6% and 16.2%, respectively. The EPS estimates for 2025 and 2026 have been trending higher over the past 60 days. Image Source: Zacks Investment Research BA stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Spirit Aerosystems Holdings, Inc. (SPR) : Free Stock Analysis Report Airbus Group (EADSY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy
June 10, 2025Announcement no. 16 BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy COPENHAGEN, DENMARK and BOSTON, MA, USA, June 10, 2025, (GLOBE NEWSWIRE) - BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR) today announced the appointment of Carsten Buhl as Chief Executive Officer (CEO) of BioPorto A/S and its subsidiaries, effective 1 September 2025, as part of the Company's succession planning strategy. BioPorto's current CEO, Peter Mørch Eriksen, will remain in his position until 1 September 2025. Following this date, Peter Mørch Eriksen will support the incoming CEO during the transition period to ensure a smooth and effective onboarding process. Carsten Buhl has spent more than 25 years in the MedTech/life science industries, recently as President of Americas at WSAudiology and part of its executive management. Further, Carsten has experience from senior leadership positions at Natus Medical Inc, Ambu and GN Store Nord. Jens Due Olsen, Chair of BioPorto, stated: "I am pleased to welcome Carsten Buhl to BioPorto. Carsten will be instrumental in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth and finalizing the clinical studies & submitting an FDA application for adult use in 2026. With a strong background in MedTech/life science, Carsten has a proven track record of driving growth, innovation, and operational excellence. Carsten will be a solid addition to the BioPorto team.' Carsten Buhl, BioPorto's incoming CEO, commented: 'I am excited to join BioPorto at this amazing point in its journey, and look forward together with the BioPorto team to materialize the full potential of the Company's biomarker tests within kidney health, critical tests that can improve the clinical and economic outcomes for patients, providers, and healthcare ecosystem globally." Jens Due Olsen added: 'I want to extend my gratitude to and thank Peter for his dedication and important contributions to BioPorto. During this second tenure, significant milestones have been achieved — including the development of a comprehensive Corporate Strategy Plan, securing revenue growth, preparation for the commercial launch of ProNephro AKI (NGAL) in the US, advancement of the clinical trial for adult use, and securing successive critical financing rounds for the Company. These accomplishments have laid a robust foundation for BioPorto's continued growth and success.' To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on Investor Relations Contacts Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@ C: +45 26368918 About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit Forward looking statement disclaimer Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as 'aim', 'anticipate', 'believe', 'intend', 'estimate', 'expect' and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully disclosed in BioPorto's periodic financial filings, including its Annual Report for 2024, particularly under the heading 'Risk Factors'. Attachment 2025 06 10 - Announcement no. 16 - UKError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
